XML 99 R29.htm IDEA: XBRL DOCUMENT v3.25.3

Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table reconciles reported revenues to net loss under the significant expense principle for the three and nine months ended September 30, 2025 and 2024:

			Three Months Ended September 30,												Nine Months Ended September 30,
			2025						2024						2025						2024
Revenues			$	12,807					$	13,542					$	31,530					$	45,694
Costs and expenses:
Total Manufacture and Supply Expenses			4,506						4,437						12,719						13,352
R&D Project expenses:
Anaphylm project expenses			912						2,601						4,604						7,448
AQST-108 project expenses			(131)						(5)						254						784
Libervant project expenses			—						(19)						—						(2)
R&D other expenses:
Personnel costs1			3,001						1,884						7,351						5,627
Other2			748						808						1,787						1,506
Total Research and Development Expenses			4,530						5,269						13,996						15,363
Selling expenses:
Personnel costs3			805						598						2,108						1,784
Other4			3,110						1,369						8,283						2,324
Total Selling expenses			3,915						1,967						10,391						4,108
General & Administrative expenses:
Personnel costs5			5,017						4,906						15,025						14,485
Other6			6,318						5,253						21,611						15,578
Total General and Administrative Expenses			11,335						10,159						36,636						30,063
Total Selling, General and Administrative Expenses			15,250						12,126						47,027						34,171
Total costs and expenses			24,286						21,832						73,742						62,886
Loss from operations			(11,479)						(8,290)						(42,212)						(17,192)
Other income/(expenses), net			(3,967)						(3,219)						(9,712)						(9,890)
Net loss before income taxes			(15,446)						(11,509)						(51,924)						(27,082)
Net loss			$	(15,446)					$	(11,509)					$	(51,924)					$	(27,082)
Comprehensive loss			$	(15,446)					$	(11,509)					$	(51,924)					$	(27,082)

1 - R&D Personnel costs include payroll expenses, share-based compensation expenses and severance

2 - Other Research and Development expenses include preclinical, consulting, maintenance, and testing fees

3 - Selling Personnel costs include payroll expenses and severance

4 - Other Selling expenses include commercialization and other related expenses

5 - G&A Personnel costs include payroll expenses, share-based compensation expenses and severance

6 - Other General and Administrative expenses include legal/patent fees, insurance fees, IT expenses, investor relations expenses, regulatory fees, facility and other costs

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration